Jared Kramer, MD
Family Medicine · St Paul, NENPI 1134105463
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $31,682 of the $41,194 with a category attached, or 76.9%. Novo Nordisk accounts for 87.6% of it on its own, with 35 other manufacturers making up the rest. 2025 is the largest year on record at $30,380, more than ten times the $994 reported in 2019. Among family medicine clinicians in NE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 424 payments — averaging $97.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$36K
- AstraZeneca$1K
- Amgen$604
- Lilly USA, LLC$447
- AbbVie$434
- Pfizer$336
- plus $2K from 30 others
What the payments were for
- Speaking & faculty fees$31,68277%
- Travel & lodging$2,9417%
- Food & beverage$6,57116%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 76 | $36,082 |
| AstraZeneca | 26 | $1,246 |
| Amgen | 45 | $604 |
| Lilly USA, LLC | 41 | $447 |
| AbbVie(2 entities) | 35 | $434 |
| Pfizer | 71 | $336 |
| Astellas Pharma US Inc | 14 | $273 |
| Johnson & Johnson(2 entities) | 15 | $256 |
| Mylan Specialty L.p. | 14 | $232 |
| Boehringer Ingelheim | 12 | $190 |
| Sanofi-aventis U.S. LLC | 10 | $152 |
| Phathom Pharmaceuticals, Inc. | 3 | $141 |
| GSK | 20 | $135 |
| Bayer | 8 | $122 |
| Dexcom, Inc. | 4 | $56 |
| Avanir Pharmaceuticals, Inc. | 3 | $42 |
| Novartis | 3 | $42 |
| Insulet Corporation | 2 | $40 |
| Gilead | 2 | $30 |
| Merck | 2 | $27 |
| Esperion Therapeutics, Inc. | 2 | $27 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $26 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $25 |
| Roche Diagnostics Corporation | 1 | $25 |
| Organogenesis Inc. | 1 | $22 |
| Abbott | 1 | $22 |
| Medtronic | 1 | $20 |
| Viatris Specialty LLC | 1 | $20 |
| Ironwood Pharmaceuticals, Inc | 1 | $19 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
| Acadia Pharmaceuticals Inc | 1 | $16 |
| Biowound Solutions, Inc. | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Genentech USA, Inc. | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
| Organon | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$41,194 in reported general payments places this provider in the 95th percentile of 981 family medicine providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 136 | $149,179 |
| EliquisApixaban | 168 | $85,539 |
| Xigduo XrDapaglifloz Propaned/Metformin | 80 | $60,483 |
| JardianceEmpagliflozin | 56 | $45,394 |
| XareltoRivaroxaban | 63 | $38,354 |
| TrulicityDulaglutide | 37 | $37,942 |
| Tresiba Flextouch U-200Insulin Degludec | 49 | $36,704 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 49 | $35,286 |
| FarxigaDapagliflozin Propanediol | 41 | $20,512 |
| NuedextaDextromethorphan Hbr/Quinidine | 11 | $20,076 |
| Repatha SureclickEvolocumab | 27 | $19,812 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 31 | $19,156 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 22 | $19,103 |
| MyrbetriqMirabegron | 53 | $16,816 |
| MounjaroTirzepatide | 14 | $16,762 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $36,082 | $159,150147 claims |
| PfizerEliquis, Abrysvo | $336 | $100,386214 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Synjardy | $190 | $79,59899 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $447 | $54,70451 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Shingrix, Arexvy | $135 | $52,991102 claims |
| Johnson & JohnsonXarelto | $256 | $38,35463 claims |
| AstraZenecaFarxiga, Symbicort | $1,246 | $25,46660 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $42 | $20,07611 claims |
| MerckJanumet Xr, Januvia | $27 | $19,67530 claims |
| Astellas Pharma US IncMyrbetriq | $273 | $16,81653 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $15 | $11,65013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 981 family medicine providers in Nebraska.
Other family medicine in St Paul
- Michael IsraelLincoln$375K
- Francisco DozonNorfolk$238K
- Randy KohlLincoln$67K
- James OmelGrand Island$67K
- Gerard StanleyOmaha$50K
- Randolph WaldmanHebron$27K
- Brian FinleyBellevue$20K
- William FitzgibbonsElkhorn$18K
- Michael BrennerSouth Sioux City$17K
- Matthew GlennLincoln$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.